I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Mail Stop Sequence, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313 on September 20,2003.

Ginger M. Grafff Date Date



PATENT

RECEIVED

SEP 1 7 2003

TECH CENTER 1600/2900

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Serial No.:

09/628,361

Filing Date:

July 18, 2000

Applicant(s):

Balasubramanium et al.

Title:

Compounds for Control of Appetite, Blood Pressure,

Cardiovascular Response, Libido, and Circadian Rhythm

Group Art Unit:

1653

Examiner:

Chih-Min Kam

Atty Docket No.:

UOC-136R

Cincinnati, Ohio 45202

September 10, 2003

Mail Stop Sequence Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313

Sir:

STATEMENT UNDER 37 C.F.R. § 1.821(f)

The information recorded in computer readable form of United States

Patent Application No. 09/628,361, filed July 18, 2000, and the paper copy of same are
identical to the written sequence listing contained in the above-referenced application and
contain no new matter.

Respectfully submitted,

WOOD, HERRON & EVANS, L.L.P.

By:

David E. Jefferies, Beg. No. 46,800

Wood, Herron & Evans, L.L.P. 2700 Carew Tower Cincinnati, OH 45202 (513) 241-2324

K:\UOC\136R\Sequencing statement.2.wpd

Application No.: 09/618,361

NOTICE TO COMPEX, WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES

Applicant must file the items indicated below within the time period set the Office action to which the Notice is attached to avoid abandonment under 35 U.S.C. § 133 (extensions of time may be obtained under the provisions of 37 CFR 1.136(a)).

The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 C.F.R. 1.821 - 1.825 for the following reason(s):

Х	1.	This application clearly fails to comply with the requirements of 37 C.F.R. 1.821-1.825. Applicant's attention is directed to the final rulemaking notice published at 55 FR 18230 (May 1, 1990), and 1114 OG 29 (May 15, 1990). If the effective filing date is on or after July 1, 1998, see the final rulemaking notice published at 63 FR 29620 (June 1, 1998) and 1211 OG 82 (June 23, 1998).
		This application does not contain, as a separate part of the disclosure on paper copy, a "Sequence Listing" as required by 37 C.F.R. 1.821(c).
		A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 C.F.R. 1.821(e).
	4.	A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 C.F.R. 1.822 and/or 1.823, as indicated on the attached copy of the marked -up "Raw Sequence Listing."
	5.	The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A Substitute computer readable form must be submitted as required by 37 C.F.R. 1.825(d).
	6.	"Sequence Listing" as required by 37 C.F.R. 1.821(e).
x	7.	Other: Compounds 38 and 50 (at pages 38 and 39) are listed, however, no "SEQ ID NO:" is given, and the sequence of SEQ ID NO:2 does not match with the sequence of compound 39. SEP 17 2003
	A	pplicant Must Provide: in initial or substitute computer readable form (CRF) copy of the "Sequence Listing".
x		n initial or substitute computer readable form (CRF) copy of the "Sequence Listing".
x	An initial or substitute paper copy of the "Sequence Listing", as well as an amendment directing its entry into the specification.	
x	A in	statement that the content of the paper and computer readable copies are the same and, where applicable, clude no new matter, as required by 37 C.F.R. 1.821(e) or 1.821(f) or 1.821(g).
		For questions regarding compliance to these requirements, please contact:

- For Rules Interpretation, call (703) 308-4216 or (703) 308-2923
- For CRF Submission Help, call (703) 308-4212
- For Patentin software Program Support:
 - HELP DESK: (703) 739-8559, ext 508, M-F, 8 AM to 5 PM EST except holidays
 - Email: PATIN21HELP@uspto.gov
 - To purchase Patentin sofftware: (703) 306-2600

PLEASE RETURN A COPY OF THIS NOTICE WITH YOUR RESPONSE